Global Leading Market Research Publisher QYResearch announces the release of its latest report “Moderate to Severe Plaque Psoriasis Medications – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Moderate to Severe Plaque Psoriasis Medications market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Moderate to Severe Plaque Psoriasis Medications was estimated to be worth US28,500millionin2025andisprojectedtoreachUS28,500millionin2025andisprojectedtoreachUS42,000 million by 2032, growing at a CAGR of 6.0% from 2026 to 2032. For dermatologists, rheumatologists, and pharmaceutical brand managers, the core business imperative lies in prescribing moderate to severe plaque psoriasis medications that address the critical need for controlling chronic, relapsing, inflammatory skin disease (affecting 2-3% of population, 125M people worldwide) with symptoms including erythematous plaques, silvery scales, pruritus (itching), pain, and psychosocial impairment (depression, anxiety, work absenteeism). Moderate to severe disease defined by body surface area (BSA) involvement (>3-10%), Psoriasis Area and Severity Index (PASI) >10, Dermatology Life Quality Index (DLQI) >10, or involvement of special areas (scalp, nails, palms, soles, genitals). Driving factors: disease severity (requires systemic therapy (biologics, oral small molecules, phototherapy) to control progression and relieve symptoms), medical needs (chronic condition requires long-term treatment (lifelong), management, and monitoring), development of science and technology (biologic agents targeting specific cytokines (tumor necrosis factor-alpha (TNF-α), interleukin-17 (IL-17), interleukin-23 (IL-23)), oral small molecules (PDE4 inhibitor, TYK2 inhibitor, JAK inhibitor), and new formulations (topical roflumilast, tapinarof)), policy support (FDA breakthrough therapy designation, EMA (European Medicines Agency) PRIME (Priority Medicines), China NMPA (National Medical Products Administration) priority review), and market demand (growing psoriasis prevalence (linked to obesity, metabolic syndrome, cardiovascular disease, mental health), biologic market expansion). Key drug classes: biologics (injectable monoclonal antibodies (mAbs)): TNF-α inhibitors (adalimumab (Humira – AbbVie), etanercept (Enbrel – Amgen / Pfizer), infliximab (Remicade – J&J)) — first generation; IL-17 inhibitors (secukinumab (Cosentyx – Novartis), ixekizumab (Taltz – Eli Lilly), brodalumab (Siliq – Valeant)) — rapid onset, high efficacy (PASI 75-100); IL-23 inhibitors (risankizumab (Skyrizi – AbbVie), guselkumab (Tremfya – J&J), tildrakizumab (Ilumya – Sun Pharma), mirikizumab (Omvoh – Eli Lilly (Crohn’s, not psoriasis))) — IL-23 p19 subunit, long dosing interval (8-12 weeks), high response rates; IL-12/23 inhibitor (ustekinumab (Stelara – J&J)). Oral small molecules: PDE4 inhibitor (apremilast (Otezla – Amgen)) — mild/moderate; TYK2 inhibitor (deucravacitinib (Sotyktu – BMS)) — selective, oral once-daily; JAK inhibitors (tofacitinib (Xeljanz – Pfizer), upadacitinib (Rinvoq – AbbVie)) — off-label. Topical creams: corticosteroids (betamethasone, clobetasol), vitamin D analogs (calcipotriene), calcineurin inhibitors (tacrolimus, pimecrolimus), PDE4 inhibitor (roflumilast (Zoryve – Arcutis)), aryl hydrocarbon receptor agonist (tapinarof (Vtama – Dermavant Sciences)). Applications: hospital clinic (dermatology specialty, rheumatology), pharmacy (retail, specialty, mail-order), online shopping mall (e-commerce, telemedicine). Key players: Janssen Biotech (US – Stelara, Tremfya, Remicade), AbbVie (US – Humira, Skyrizi), Sandoz (Switzerland – biosimilars (adalimumab, etanercept, infliximab)), Amgen (US – Enbrel, Otezla, biosimilars), Eli Lilly (US – Taltz, Olumiant (baricitinib)), Novartis (Switzerland – Cosentyx), Sun Pharmaceutical Industries (India – Ilumya, biosimilars), UCB, Inc (Belgium – Cimzia), Dermavant Sciences (US – Vtama), GSK (UK – Benlysta (lupus not psoriasis)). The market is driven by biologic efficacy (PASI 90-100), long safety record, and biosimilar entry (adalimumab, etanercept, infliximab), reducing cost, increasing access.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/releases/5975532/moderate-to-severe-plaque-psoriasis-medications
1. Market Drivers: Biologic Efficacy, Biosimilars, and Oral Small Molecules
Several powerful forces are driving the moderate to severe plaque psoriasis medications market:
Biologic efficacy (IL-17, IL-23 inhibitors) – PASI 90 achieved in 60-80% patients, PASI 100 in 30-50%. Rapid onset (4-12 weeks).
Biosimilar entry (adalimumab, etanercept, infliximab) – Humira biosimilars (Amjevita, Hyrimoz, Cyltezo, Hulio) reduce cost 30-50%, increase access.
Oral TYK2 inhibitor (Sotyktu – deucravacitinib) – First oral selective TYK2 inhibitor approved (2022). PASI 75 superior to Otezla, placebo. Joint pain improvement (psoriatic arthritis).
Recent market data (December 2025): According to Global Info Research analysis, injectable biologics dominate with approximately 70% revenue share (TNF, IL-17, IL-23, IL-12/23). Oral small molecules 20% share (apremilast (Otezla), deucravacitinib (Sotyktu)). Topical creams 10% share (mild/moderate, low potency). Hospital clinic (dermatologist prescription) largest application (80% share). Pharmacy (specialty, mail-order) 15% share. Online shopping mall 5% share. North America (US) largest market (45% share). Europe 30% share. Asia-Pacific (China, Japan) 20% share (fastest-growing 7-8% CAGR). AbbVie (Humira, Skyrizi), J&J (Stelara, Tremfya), Novartis (Cosentyx), Eli Lilly (Taltz), Amgen (Enbrel, Otezla), Sun Pharma (Ilumya, biosimilars), Sandoz (biosimilars), UCB (Cimzia), Dermavant (Vtama) leaders.
2. Drug Classes and Key Specifications
| Drug Class | Examples (Brand) | Mechanism | Route | Dosing | PASI 90 (16 weeks) | Share |
|---|---|---|---|---|---|---|
| IL-17 Inhibitor | Secukinumab (Cosentyx), ixekizumab (Taltz) | IL-17A monoclonal antibody | Subcutaneous | Loading then monthly | 60-75% | ~25% |
| IL-23 Inhibitor | Risankizumab (Skyrizi), guselkumab (Tremfya) | IL-23 p19 monoclonal antibody | Subcutaneous | 4 weeks loading then 8-12 week maintenance | 70-80% | ~25% |
| TNF-α Inhibitor | Adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade) | TNF-α monoclonal antibody | SC, IV | Weekly, biweekly, 8 weeks | 50-60% | ~15% |
| Oral TYK2 | Deucravacitinib (Sotyktu) | TYK2 inhibitor (allosteric) | Oral | Once daily | 35-45% | ~10% |
Key trials: CLEAR, ECLIPSE, POETYK PSO-1, POETYK PSO-2, FIXTURE, ERASURE, AMAGINE. PASI (Psoriasis Area and Severity Index), PGA (Physician Global Assessment), BSA (Body Surface Area), DLQI (Dermatology Life Quality Index). Psoriatic arthritis (PsA) indication (Cosentyx, Taltz, Skyrizi, Tremfya, Cimzia). Adverse events: injection site reaction, nasopharyngitis, headache. IL-17i increased risk Candida infection. Risk of latent tuberculosis reactivation (TNF inhibitors screen). Suicidal ideation warning (applies to some IL-17, IL-23). Pregnancy category B/C.
Exclusive observation (Global Info Research analysis): Moderate to severe plaque psoriasis market is dominated by AbbVie (Humira, Skyrizi) and J&J (Stelara, Tremfya). Humira biosimilars (2023 US, earlier Europe) eroded market share. Skyrizi (IL-23) fastest-growing due to high PASI response (90-100%), extended dosing (12 weeks). Deucravacitinib (Sotyktu) first oral TYK2 (2022). Roflumilast (Zoryve) topical PDE4 (2022). Tapinarof (Vtama) topical AhR (2022). Systemic corticosteroids avoided (rebound). Biologics have revolutionized psoriasis treatment.
User case – biologic therapy (December 2025): US patient (45 yo) with chronic plaque psoriasis (BSA 20%, PASI 18). Failed topical, phototherapy, Otezla. Prescribed Skyrizi (risankizumab) subcutaneous: loading dose (150mg week 0,4), then maintenance (150mg every 12 weeks). PASI 90 achieved week 16. Maintained year 2.
User case – oral TYK2 (January 2026): UK patient (38 yo, moderate psoriasis (BSA 8%, PASI 10)). Prefers oral tablet. Deucravacitinib (Sotyktu) 6mg BID. PASI 75 week 16. No injection site reactions.
3. Key Challenges and Technical Difficulties
High cost of biologics (US$30,000-80,000 per year) – Biosimilars reduce cost. Insurance prior authorization, step therapy. Medicare Part D.
Infection risk (tuberculosis, Candida, opportunistic) – Screening (latent TB, hepatitis B, C). Prophylaxis.
Technical difficulty – loss of response (immunogenicity, anti-drug antibodies): Biologic failure (primary, secondary). Switch mechanism.
Technical development (October 2025): Sandoz (Switzerland) launched adalimumab biosimilar (Hyrimoz) subcutaneous autoinjector citrate-free version. Less injection site pain.
4. Competitive Landscape
Key players include: Janssen Biotech (US – Stelara, Tremfya, Remicade), AbbVie (US – Humira, Skyrizi), Sandoz (Switzerland – biosimilars), Amgen (US – Enbrel, Otezla), Eli Lilly (US – Taltz, Olumiant), Novartis (Switzerland – Cosentyx), Sun Pharmaceutical Industries (India – Ilumya, biosimilars), UCB, Inc (Belgium – Cimzia), Dermavant Sciences (US – Vtama), GSK (UK). AbbVie, J&J, Novartis, Eli Lilly leaders.
Regional dynamics: North America (J&J, AbbVie, Amgen, Eli Lilly, Dermavant). Europe (Novartis, UCB, Sandoz, GSK). Asia-Pacific (Sun Pharma India, biosimilars, originators). Humira biosimilars widely available.
5. Outlook
Moderate to severe plaque psoriasis medications market will grow at 6.0% CAGR to US$42.0 billion by 2032, driven by biologic efficacy, biosimilar access, and oral TYK2. Technology trends: IL-23 inhibitors (Skyrizi, Tremfya) gaining share, IL-17 inhibitors mature, TNF biosimilars decreasing price. Asia-Pacific growth fastest (7-8% CAGR). Injectable biologics remain dominant.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
